Physician profile
Emmanuel E Ugbarugba
NPI 1831353283
$2,670.35
in general payments reported to CMS, 2019-2025
25 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $347 · 2022: $627 · 2023: $850 · 2024: $462 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,680 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,680.04 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $899.42 | 2021-2025 | Skyrizi, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.80 | 2021-2023 | Xifaxan |
| Qol Medical, LLC | $228.84 | 2021-2025 | Sucraid |
| Genzyme Corporation | $201.87 | 2022-2025 | |
| Janssen Biotech, INC. | $178.36 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $152.24 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $122.15 | 2021-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $98.56 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $59.03 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.42 | 2021-2023 | Bridion, Dificid |
| Celgene Corporation | $54.92 | 2022-2023 | Zeposia |
| Daiichi Sankyo INC. | $50.25 | 2022-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $46.50 | 2025 | Voquezna |
| Amgen INC. | $37.60 | 2021-2023 | Amjevita, Avsola |
| Pfizer INC. | $36.72 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $31.59 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $29.71 | 2024 | |
| Tempus Ai, INC | $28.78 | 2025 | Xt Cdx |
| Celltrion USA INC. | $21.04 | 2025 | Vegzelma |
| Braintree Laboratories, INC. | $20.92 | 2022 | |
| Lilly USA, LLC | $19.59 | 2025 | Omvoh |
| Organon LLC | $19.57 | 2025 | Hadlima, Renflexis |
| Redhill Biopharma INC. | $15.30 | 2022 | |
| Evoke Pharma, INC. | $14.68 | 2023 | Gimoti |
| Alfasigma USA, INC. | $11.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emmanuel Ugbarugba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.